tralokinumab   Click here for help

GtoPdb Ligand ID: 8001

Synonyms: Adbry® | Adtralza® | BAK1.1 [2] | CAT-354 [2] | tralokinumab-ldrm
Approved drug Immunopharmacology Ligand
tralokinumab is an approved drug (EMA & FDA (2021))
Compound class: Antibody
Comment: Tralokinumab is a monoclonal antibody directed against interleukin 13 (IL-13), a cytokine secreted by T helper cells, and which is a central mediator of the physiological changes induced by allergic inflammatory reactions [4] Binding affinity of tralokinumab was optimised (aka affinity maturation) using an in vitro ribosome display technology [2].
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record.
Classification Click here for help
Compound class Antibody
Approved drug? Yes. FDA (2021)  |  EMA (2021)
International Nonproprietary Names Click here for help
INN number INN
9235 tralokinumab
Synonyms Click here for help
Adbry® | Adtralza® | BAK1.1 [2] | CAT-354 [2] | tralokinumab-ldrm
Database Links Click here for help
Specialist databases
IMGT/mAb-DB 171
Other databases
GtoPdb PubChem SID 249565681
Search PubMed clinical trials tralokinumab
Search PubMed titles tralokinumab
Search PubMed titles/abstracts tralokinumab
Wikipedia Tralokinumab